CD300E and acute myeloid leukemia: To quantify whether monocytic AML can be accurately distinguished from AML with more stem cell-like phenotypes, we plotted CD14+ monocyte percentages as determined by deconvolution against MFI values of antibodies of monocytic markers (CD11b, CD64, IREM2, and CD14) on all BM cells without gating, and observed statistically significant correlations for 3 markers (CD11b, CD64, IREM2), with CD64 being most significant (R2 = 0.43, P < 0.001) (Fig. S1F).